Zevra Therapeutics to Report Second Quarter 2024 Financial Results
July 30, 2024 08:38 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 09, 2024 09:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
Zevra Therapeutics Expands Executive Leadership Team
June 25, 2024 07:30 ET
|
Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
June 03, 2024 11:00 ET
|
Zevra Therapeutics
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on...
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
April 03, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zevra Therapeutics, Inc....
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
November 20, 2023 07:30 ET
|
Zevra Therapeutics
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET
|
Zevra Therapeutics
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results.
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
October 19, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global...
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
October 10, 2023 07:30 ET
|
Zevra Therapeutics
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
October 05, 2023 07:30 ET
|
Zevra Therapeutics
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra...